El En SpA
OTC:ELEAF
El En SpA
OTC:ELEAF
Price:
9.8 USD
Market Closed
Updated:
May 12, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
9.6
Current
11.3
Median
12.9
Industry
Lower
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=9.6
Enterprise Value
/
814.4m
EBITDA
84.5m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| IT |
|
El En SpA
OTC:ELEAF
|
920.8m USD | 9.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
182.2B USD | 19.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
137.2B USD | 56.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.9B USD | 24.3 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.1B USD | 13.9 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
108.3B USD | 30.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.1B USD | 18.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
58.7B EUR | 18.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
52.2B USD | 26.8 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
368.5B CNY | 27.8 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
50.3B USD | 58.8 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
8.3
2-Years Forward
EV/EBITDA
7.7
3-Years Forward
EV/EBITDA
7.1
You don't have any saved screeners yet
